Khosravi M. Journal of Guilan University of Medical Sciences. 2005 Jan 15; 13(52):65-70.
Experimental and Clinical Transplantation, 2006 Jun; 4(1):458-61.
Cytomegalovirus Disease with Atypical Presentation in a Renal Transplant Patient: Case Report
Masoud Khosravi,1 Ali Nobakht,2 Abdolah R Nikokar3
1Division of Nephrology, Gilan University of Medical Sciences, Gilan, Iran
2Division of Nephrology, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
3Division of Pathology, Gilan University of Medical Sciences, Gilan, Iran
Address reprint requests to:
Masoud Khosravi, Golsar, Street 142, No: 25, Postal Code: 4165763355, Rasht, Iran
Phone: 00 989 11 131 5796
Fax: 00 981 31 772 1728
E-mail: drmasoudkhosravi@yahoo.com
ABSTRACT Full-Text PDF
Infection is a major problem after kidney transplantation. Cytomegalovirus (CMV) is the most common viral infection affecting transplant patients. This report presents a rare clinical manifestation of CMV in the form of a hemorrhoid in a 58-year-old woman. One week after undergoing an external hemorrhoidectomy, the patient presented with fever, leukopenia, and thrombocytopenia. Pathological analysis showed CMV in the hemorrhoidal tissue, which was confirmed via a positive PP65 antigenemia assay. Therapy with ganciclovir (250 mg IV b.i.d. for 2 weeks) was started. The patient’s response to treatment was good, and she has been doing well since that time. Her plasma creatinine level 2 years later was 79.2 µmol/L (normal range, 53-106 µmol/L). Physicians must always be aware of the hatahomads of CMV in immunocompromised patients with typical, and even with atypical, presentations. Taking into consideration the statement, “prophylaxis precedes treatment,” nephrologists must try to detect CMV in their patients (especially during the first 6 months after transplantation) prior to the appearance of any clinical manifestations. If CMV is detected, pre-emptive therapy with ganciclovir should be started.
Key words: Cytomegalovirus infection, Kidney transplantation, Immunosuppression, Endothelial cells
Khosravi M, Bastani B. Transplant Proc. 2007 May; 39(4):1263-6. doi:10.1016/j.transproceed.2007.03.036
Transplantation Proceedings, 2007 May; 39(4):1263-6. doi: 10.1016/j.transproceed.2007.03.036
Acute renal failure due to leptospirosis in a renal transplant recipient: a brief review of the literature.
M. Khosravi and B. Bastani
ABSTRACT Full-Text PDF
We present the case of a 43-year-old renal transplant patient who presented with fever, malaise, pruritus, headache, and severe jaundice of 3-week duration following work in a rice field. He was found to have acute renal failure and severe hyperbilirubinemia with a positive serum leptospira antibody titer, making the diagnosis of Weil’s disease. The patient responded to reduction in immunosuppressive medications and intravenous penicillin therapy with no need for dialysis. This is the second case of leptospirosis in a kidney transplant patient reported in the English literature.
Monfared A, Ghods AJ. Iran J Kidney Dis. 2008 Apr; 2(2):95-8.
Nafar M, Lessan-Pezeshki M, Shahbazian H, Pour-Reza-Gholi F, Firouzan A, Ahmadpour P, Makhdomi K, Ghafari A, Ardalan MR, Roozbeh J, Jalalzadeh M, Ghadiani MH, Khosravi M, Razeghi E. Int J Nephrol Urol. (Nephro-Urology Monthly) 2009 June; 1(1, Summer):33-38.
Aghajanzadeh M, Monfared A, Mokhtari GR, K Lebady M, Poorreza F, Orangpour R. Medical Journal of the Islamic Republic of Iran (MJIRI). 2009 May 15; 23(1):48-52.
Mokhtari G, Pourreza F, Asgari SA, Hemmati H, Enshaei A, Emadi SA, Afsharimoghaddam A. UroToday International Journal. 2010 Oct 1; 3(5). doi:10.3834/uij.1944-5784.2010.10.04
Rostami Z, Einollahi B, Lessan-Pezeshki M, Nourbala MH, Nemati E, Pourfarziani V, Shahbazian H, Khosravi M, Jalalzadeh M. Transplant Proc. 2011 Mar; 43(2):588-9. doi:10.1016/j.transproceed.2011.01.073.
Transplantation Proceedings, 2011 Mar; 43(2):588-9. doi:10.1016/j.transproceed.2011.01.073.
Old male living renal transplant recipients more likely to be at risk for colorectal cancer.
Z. Rostami, B. Einollahi, M. Lessan-Pezeshki, M.H. Nourbala, E. Nemati, V. Pourfarziani, H. Shahbazian, M. Khosravi, and M. Jalalzadeh
ABSTRACT Full-Text PDF
Background: The development of posttransplant malignancy is a well-recognized complication of kidney transplantation due to immunosuppressive therapy. The literature on colorectal malignancy in living renal transplant recipients are limited; most of the data have been collected from deceased donor cases. As living kidney donation is now growing, we sought to define the characteristics and pattern of gastrointestinal malignancy among this group.
Methods: This cross-sectional, multicenter study analyzed the incidence and characteristics of colorectal malignancy among 17 patients with gastrointestinal malignancy after living donor renal transplantation between 1985 and 2009 in Iran. We observed a new-onset, biopsy-proven colorectal malignancy in eight patients of mean age 49.6±10.3 years (range=27–60) at transplantation time and a mean age of 61.1±8.6 years (range=53.4 –78.6) at cancer diagnosis.
Results: The cumulative incidence rate of colorectal malignancy of 0.03% was restricted to the male gender (100%), all of whom had functioning grafts. The mean period from transplantation to diagnosis was 99.7±10.4 months (range=5–284). The majority of the recipients were aged more than 50 years (n=5) and the most frequent immunosuppressive drug was azathioprine (n=5); none had received antithymocyte globulin/antilymphocyte globulin. It was mostly a late-onset malignancy with 50% of recipients presenting beyond 5 years from transplantation. They were followed for a mean of 9.2±2.4 (range=6–12) months after cancer diagnosis with three patients having succumbed within 9 months.
Conclusion: Due to the long latency after transplantation and the poor outcomes of colorectal malignancy these patients require long-term screening tests for early detection and due to their poor outcomes a new therapeutic approach.
Khosravi M, Golchai J, Mokhtari G. Clin Transplant. 2011 May-Jun; 25(3):395-400. doi:10.1111/j.1399-0012.2010.01284.x.
Clin Transplant. 2011 May-Jun; 25(3):395-400. doi:10.1111/j.1399-0012.2010.01284.x.
Muco-cutaneous manifestations in 178 renal transplant recipients.
Masoud Khosravi, Javad Golchai and Gholamreza Mokhtari
Department of Renal Transplantation and Department of Dermatology, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran
Corresponding author: Dr. Masoud Khosravi, Assistant Professor, Nephrologist, Nephrology Department, Guilan University of Medical Sciences, Renal Transplantation Ward, Razi Hospital, Sardar Gangal Street, 414489565 Rasht, Iran.
Tel.: 00981315537500; fax: 00981315530169; e-mail: masoud@gums.ac.ir
ABSTRACT Full-Text PDF
Introduction: Mucosal membrane and skin can be affected by immunosuppressive drug(s) and immunosuppression itself. The spectrum of muco-cutaneous lesions can range from malignancy at one end to infection, iatrogenic lesions, and esthetic effects on the other end.
Method: In Razi Hospital of Guilan University of Medical Sciences, a cross-sectional study for the detection of muco-cutaneous lesions in 178 renal transplant recipients (RTRs) was conducted from the years 2001 to 2006. Biopsy and skin scraping according to the type of skin lesions were performed.
Results: A total of 31 RTRs (25%) had normal skin. Iatrogenic lesions were the most common (70%) followed by infectious lesions (57%), and miscellaneous skin lesions were exhibited by 26% of the patients. Among the iatrogenic skin lesions, gingival hyperplasia was the most common lesion (48%), followed by hypertrichosis and acne. Malignant lesions (biopsy proven) were recorded in seven patients (5%). Four patients were found to have Kaposi_s sarcoma, and three patients were identified with basal cell carcinoma.
Conclusion: Our results showed that muco-cutaneous lesions are crucial problems with RTRs. Attending physicians must pay close attention to skin care regularly and consider reduction of immunosuppression to a safe level, and patient must have self-checkups.
Key words: immunosuppression – mucocutaneous lesions – renal transplantation
Monfared A, Kohani M, Kazemnejad E, Khosravi M. Iran J Kidney Dis. 2011 November (Abstract Book of the 13th Congress of Nephrology, Dialysis, and Transplantation; YAZD 2011); 5(Supplement 2):25-25.
Iranian Journal of Kidney Diseases | Volume 5 | Supplement 2 | November 2011
13th International Congress of Nephrology, Dialysis and Transplantation—Poster Presentations
P204
Evaluation of Graft Survival Renal Transplant Ward of Razi Hospital, Rasht, North of Iran, From 1999 to 2010
Monfared A, Kohani M, Kazemnejad E, Khosravi M
Urology Research Center, Guilan University of Medical Sciences, Iran
Introduction: Renal transplantation is the modality of choice for renal replacement therapy in the majority of ESRD patients. The survival of transplant kidney was improved significantly with introduce of new immunosuppressive regimens. In this study, we evaluated the renal transplant recipients’ graft survival in Razi hospital of Rasht in North of Iran, from 1999 to 2010.
Methods: All kidney transplant recipients in our center (n = 273) were studied. The demographic data were collected. Then 1-, 5-, and 10-year survival analyzed with analysis survival data and Kaplan-Meier curve. Chi-square test, Independent t test, and Mann-Whitney test were used for analysis of variants.
Results: In the study, 1-, 5-, and 10-year survival was 92.6%, 88%, and 77.5%, resectively. All grafts donated from living donors except 1 case. Delayed graft function significantly correlate with graft survival (P < .001).
Conclusions: In this study, 1-year survival was 92% and compared with multicenter study in USA (93.9%) showed good situation in this center. In addition, results of this study about effect of delayed graft function on graft survival are same to a study in Labafinejad hospital from 1985 to 2005.
Monfared A, Atrkar Roshan Z, Salari A, Asadi F, Lebadi M, Khosravi M, Besharati S. Exp Clin Transplant. 2012 Apr; 10(2):105-9. doi:10.6002/ect.2011.0117
Experimental and Clinical Transplantation, 2012 Apr; 10(2):105-9. doi: 10.6002/ect.2011.0117
QT intervals in patients receiving a renal transplant.
Ali Monfared,1 Zahra Atrkar Roshan,1 Arsalan Salari,2 Farshad Asadi,1Mohammadkazem Lebadi,1 Masoud Khosravi,1 Sepiedeh Besharati2
From the 1Urology Research Center, and the 2Cardiology Research Center, Guilan University of Medical Sciences, Urology Research Center, Razi Hospital, Rasht, Iran
Address reprint requests to: Ali Monfared, Urology Research Center, Guilan University of Medical Sciences, Urology Research Center, Razi Hospital, Sardar Jangal Street, Rasht, Iran
Phone: +98 911 3362634
Fax: +98 131 5525259
E-mail: drmonfared2009@gmail.com
ABSTRACT Full-Text PDF
Objectives: Cardiovascular disease is the most-common cause of mortality in patients with end-stage renal disease and renal transplant. Prolongation of QTcmax and QTc dispersion are risk factors of cardiac arrhythmias and mortality. This study compares the changes of QT parameters before hemodialysis, after hemodialysis, and after renal transplant.
Materials and Methods: Patient candidates for renal transplant were selected. Mean serum electrolyte and 12-lead electrocardiogram were recorded (1) immediately, (2) before and, (3) after the last dialysis session before renal transplant, (4) and 2 weeks after a kidney transplant in 34 patients with normal graft function (plasma Cr ≤ 176.8 µmol/L). Each QT interval was corrected for the patient’s heart rate using Bazett’s formula. The QT parameters (QTd, QTcd, QTcmax) were compared between prehemodialysis, posthemodialysis, and 2 weeks after renal transplant using a paired t test and a general liner model repeated measure. The correlation between QT parameter changes and serum electrolyte and acid-base alternation was analyzed.
Results: The corrected maximal QT interval (QTcmax) decreased significantly after successful renal transplant compared to prehemodialysis (P=0.002) and posthemodialysis (P=0.003) with a paired t test and a General Liner Model Repeated Measure (P<0.001) between the 3 groups. Also, the mean of QTcmax decreased significantly after renal transplant (P=0.001) compared to what it was before hemodialysis and after hemodialysis. There was a significant correlation (r=-0.37) between reduction of QTcmax and serum Ca level (P=0.01) in postrenal transplant period.
Conclusions: Renal transplant with normal graft function decrease QTcmax compared to prehemodialysis and posthemodialysis that may correlate with normalization of electrolytes from the uremic state of the normal kidney function.
Key words: QT interval, Renal transplant, Hemodialysis, Cardiovascular disease, Repolarization
Einollahi B, Rostami Z, Nourbala MH, Lessan-Pezeshki M, Simforoosh N, Nemati E, Pourfarziani V, Beiraghdar F, Nafar M, Pour-Reza-Gholi F, Mazdeh MM, Amini M, Ahmadpour P, Makhdoomi K, Ghafari A, Ardalan MR, Khosroshahi HT, Oliaei F, Shahidi S, Abbaszadeh S, Fatahi MR, Hiedari F, Makhlogh A, Azmandian J, Samimagham HR, Shahbazian H, Nazemian F, Naghibi M, Khosravi M, Monfared A, Mosavi SM, Ahmadi J, Jalalzadeh M. J Cancer. 2012; 3:246-56. doi:10.7150/jca.3042.
Journal of Cancer, 2012; 3: 246-256. doi: 10.7150/jca.3042
Incidence of malignancy after living kidney transplantation: a multicenter study from Iran.
Behzad Einollahi1, Zohreh Rostami1, Mohammad Hossein Nourbala1, Mahboob Lessan-Pezeshki2, Naser Sim-foroosh3, Eghlim Nemati1, Vahid Pourfarziani1, Fatemeh Beiraghdar1, Mohsen Nafar3, Fatemeh Pour-Reza-Gholi3, Mitra Mahdavi Mazdeh2, Manochehr Amini2, Pedram Ahmadpour3, Khadijeh Makhdoomi4, Ali Ghafari4, Mohammad Reza Ardalan5, Hamid Taebi Khosroshahi5, Farshid Oliaei6, Shahrzad Shahidi7, Shahin Abbaszadeh1, Mohammad Reza Fatahi1, Fatemeh Hiedari1, Atehieh Makhlogh8, Jalal Azmandian9, Hamid Reza Samimagham10, Heshmatollah Shahbazian11, Fatemeh Nazemian12, Massih Naghibi12, Masoud Khosravi13, Ali Monfared13, Seyed Majid Mosavi14, Javad Ahmadi15, Mojgan Jalalzadeh16
1. Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
2. Departement of Nephrology, Tehran University of Medical Sciences, Tehran, Iran.
3. Departement of kidney transplantation, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4. Departement of Nephrology, Urmia University of Medical Sciences, Urmia, Iran.
5. Departement of Nephrology, Tabriz University of Medical Sciences, Tabriz, Iran.
6. Departement of Nephrology, Babol University of Medical Sciences, Babol, Iran.
7. Departement of Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran.
8. Departement of Nephrology, Sari University of Medical Sciences, Sari, Iran.
9. Departement of Nephrology, Kerman University of Medical Sciences, Kerman, Iran.
10. Departement of Nephrology, Bandar Abbas University of Medical Sciences, Bandar Abbas, Iran.
11. Departement of Nephrology, Ahvaz University of Medical Sciences, Ahvaz, Iran.
12. Departement of Nephrology, Mashhad University of Medical Sciences, Mashhad, Iran.
13. Departement of Nephrology, Rasht University of Medical Sciences, Rasht, Iran.
14. Departement of Nephrology, Ghom University of Medical Sciences, Ghom, Iran.
15. Departement of Nephrology, Artesh University of Medical Sciences, Tehran, Iran.
16. Departement of Nephrology, ZanjanUniversity of Medical Sciences, Zanjan, Iran.
Corresponding author: Zohreh Rostami, MD. Nephrology and Urology
Received: 2011.05.21; Accepted: 2011.08.09; Published: 2012.06.05
ABSTRACT Full-Text PDF
Malignancy is a common complication after renal transplantation. However, limited data are available on post-transplant malignancy in living kidney transplantation. Therefore, we made a plan to evaluate the incidence and types of malignancies, association with the main risk factors and patient survival in a large population of living kidney transplantation. We conducted a large retrospective multicenter study on 12525 renal recipients, accounting for up to 59% of all kidney transplantation in Iran during 22 years follow up period. All information was collected from observation of individual notes or computerized records for transplant patients. Two hundred and sixty-six biopsy-proven malignancies were collected from 16 Transplant Centers in Iran; 26 different type of malignancy categorized in 5 groups were detected. The mean age of patients was 46.2±12.9 years, mean age at tumor diagnosis was 50.8±13.2 years and average time between transplantation and detection of malignancy was 50.0±48.4 months. Overall tumor incidence in recipients was 2%. Kaposis’ sarcoma was the most common type of tumor. The overall mean survival time was 117.1 months (95% CI: 104.9-129.3). In multivariate analysis, the only independent risk factor associated with mortality was type of malignancy. This study revealed the lowest malignancy incidence in living unrelated kidney transplantation.
Key words: malignancy, kidney transplantation, incidence.
Monfared A, Kohani M, Khosravi M, Orangpour R, Mokhtari GR. Transplantation. 2012 Nov 27 (Supplement: Meeting Abstracts of the 24th International Congress of the Transplantation Society, Berlin, Germany); 94(10S):1088.
Evaluation of Graft Survival and Related Factors among Renal Transplant Recipients in North of Iran from 1999 to 2010
Monfared A.1, Kohani M.2, Khosravi M.1, Orangpour R.3, Mokhtari G.R.4
1Guilan University of Medical Science, Nephrology, Rasht, Iran, Islamic Republic of, 2Guilan University of Medical Science, Internal Medicine, Rasht, Iran, Islamic Republic of, 3Guilan University of Medical Science, Pediatric, Rasht, Iran, Islamic Republic of, 4Guilan University of Medical Science, Urology, Rasht, Iran, Islamic Republic of
ABSTRACT PDF
Introduction: Renal transplantation is the modality of choice for renal replacement therapy in the majority of ESRD patients. The survival of transplant kidney was improved significantly with introduce of new immunosuppressive regimens. The determinators of graft survival are relatively known, but conflicting results have been reported. In this study we evaluated graft survival among renal transplant recipients in Razi Hospital of Rasht in North of Iran from 1999 to 2010.
Methods: All kidney transplant recipients in our center (n=273) were studied. The effect of the following parameters on graft survival including sex, donor age, recipient age, cause of renal failure, panel-reactive antibody titer, delayed graft function (DGF) and diabetes mellitus was investigated. Then 1, 5, and 10 years survival analyzed with “Analysis Survival Data” and “Kaplan-Meier curve”. Χ2 test, Independent t-test and Mann-Whitney test were used for analysis of variates.
Results: In this study 1 year survival was 92.6±1.6%, 5years survival was 88±2.1% and 10 years survival was 77.5±3.9%. All grafts were donated from living donor and all of them were non relative. Delayed graft function and diabetes mellitus significantly correlate with short term and long term graft survival (P<0.001). For example one year graft survival among patients with DGF and diabetes mellitus was respectively 50.8±9.89% and 79.6±7.49%. Also in Cox regression model, donor age affects on prediction of graft survival.
Conclusion: In this study 1 year survival (92/6 1/6%), compared with a multicenter study in USA (93/9%) showed good situation in this center. Also results of this study about effect of delayed graft function on graft survival are similar to many studies. Therefore, in order to improve the long-term graft survival, scientific efforts should focus on increase our understanding of delayed graft function.
Citation: Monfared A, Kohani M, Khosravi M, Orangpour R, Mokhtari GR. Evaluation of graft survival and related factors among renal transplant recipients in north of Iran from 1999 to 2010: 409. Transplantation. 2012 Nov 27 (Supplement: Meeting Abstracts of the 24th International Congress of the Transplantation Society, Berlin, Germany); 94(10S):1088.
Salari A, Monfared A, Fahim SH, Khosravi M, Lebadi M, Mokhtari G, Pourreza F, Shakiba M. Transplant Proc. 2012 Dec; 44(10):3007-12. doi:10.1016/j.transproceed.2012.03.060.
Monfared A, Azimi SZ, Kazemnezhad E, Khosravi M, Lebadi M, Mirzajani E, Ashtiani MN. Transplantation. 2014 Jul 15; 98(1):66-71. doi:10.1097/01.TP.0000443222.82207.3d.
Rostami S, Monfared A, Pourreza F, Kazemnezhad E, Khosravi M, Lebadi M, Kohani M, Mokhtari G, Hemmati H, Orangpour R, Rahimifar S. International Journal of Urology 2014 Dec 1 (Supplement: Abstracts of the 12th Asian Congress of Urology of the Urological Association of Asia, December 5th-9th, 2014, Kish Island, Iran. published online: 26 DEC 2014. doi:10.1111/iju.12708_2); 21(S2):A263-A263.
International Journal of Urology (2014) 21. Suppl 2. Page A263
Abstracts of the 12th Asian Congress of Urology of the Urological Association of Asia, December 5th-9th, 2014, Kish Island, Iran
OP.8.8Dec.8
Sadegh Rostami, Ali Monfared, Farshid Pourreza, Ehsan Kazemnezhad, Masoud Khosravi, Mohammadkazem Lebadi, Maryam Kohani, Gholamreza Mokhtari, Hossein Hemmati, Reza Orangpour, Shahrzad Rahimifar
ABSTRACT PDF
Aim: to determine graft survival rate and possible related factors in 273 living donor renal transplant recipients in a single center from 1999 to 2010.
Methods: Organ survival and demographic characteristics and variables that may affect graft survival rate were evaluated in all renal allograft recipients in Razi Hospital of Rasht in North of Iran. Chi-square, Independent T-Test and Mann-Whitney were used for analysis of variates. Survival rate was estimated by “Kaplan-Meier method”, and Tarone-Ware test were applied for comparing survival rates. Multivariate analysis was also done by COX regression model.
Results: In this study, 1-, 5- and 10 year graft survival rates were 92.6±1.6, 88±2.1 and 77.5±3.9%, respectively. Delayed graft function was significantly correlated with graft survival rate (P<0.001). Furthermore, It was the only statistically significant predictor of graft loss (p<.00). Worse graft survival rate was observed in patients with diabetes (p<0.018).
Conclusions: Although the survival rate in our center is comparable with the reports of other great centers in the world, focusing on Modification of some variables may improve transplant outcomes.
Citation: Rostami S, Monfared A, Pourreza F, Kazemnezhad E, Khosravi M, Lebadi M, Kohani M, Mokhtari G, Hemmati H, Orangpour R, Rahimifar S. Allograft survival rate and analysis of predictor factors in kidney transplant recipients from living donors. International Journal of Urology 2014 Dec 1 (Supplement: Abstracts of the 12th Asian Congress of Urology of the Urological Association of Asia, December 5th-9th, 2014, Kish Island, Iran. published online: 26 DEC 2014. doi:10.1111/iju.12708_2); 21(S2):A263-A263.
Monfared A, Monfared A, Azimi SZ, Kazemnezhad E. International Journal of Urology 2014 Dec 1 (Supplement: Abstracts of the 12th Asian Congress of Urology of the Urological Association of Asia, December 5th-9th, 2014, Kish Island, Iran. published online: 26 DEC 2014. doi:10.1111/iju.12708_2); 21(S2):A268-A268.
Monfared A, Azimi SZ, Kazemnezhad E. Transplant International. 2015 Nov 1 (Special Issue: Abstracts of the 17th Congress of the European Society for Organ Transplantation 13-16 September 2015, Brussels, Belgium. Published online: 17 NOV 2015. doi:10.1111/tri.12702); 28(S4):537-537.
Abstracts of the 17th Congress of the European Society for Organ Transplantation
P382
Ali Monfared, Seyyede Zeinab Azimi, Ehsan Kazemnezhad
Urology Research Center, Guilan University of Medical Sciences
Introduction: Statins improve prognosis in patients with coronary heart diseases by decreasing the incidence of vascular events. Excess prevalence of hyperhomocysteinemia, an independent risk factor of cardiovascular diseases, has been observed in stable renal transplant recipients (RTR). The objective of our study was to evaluate the association between plasma total homocysteine (tHcy) levels and atorvastatin in RTRs.
Method: We performed a retrospective cross-sectional study in 148 cyclosporine treated stable RTRs. We compared tHcy level in RTRs with and without atorvastatin.
Results: Mean tHcy levels were lower in patients with atorvastatin (20–40 mg/day) compared to nonusers (15.06±5.65 μmol/L, 17.91±10.85; P=0.04). The comparison of the group of 86 patients with atorvastatin and 62 non-users revealed that those subjects with atorvastatin were older, with higher HDL levels, eCrCl and BMI. They were more likely to have diabetes, higher systolic blood pressure and CsA trough level (C0). The association between lower tHcy levels and atorvastatin was confirmed in the multivariate regression model (P=0.004). However tHcy levels were negatively associated with serum folate (P=0.0001) and vitamin B12 levels (P=0.001) and positively with serum BUN (P=0.0001) and diastolic blood pressure (P=0.024) as well.
Conclusion: These data support the association between lower tHcy levels and atorvastatin usage in RTRs. Further clinical trials are recommended to clarify homocysteine lowering effect of atorvastatin.
Model | β Coefficients ± SE | t | p | 95% Confidence interval for β |
Constant | 12.22 ± 2.06 | 5.93 | 0.000 | 8.15–16.29 |
Atorvastatin | 2.85 ± 1.37 | 2.08 | 0.040 | 0.14–5.59 |
Citation: Monfared A, Azimi SZ, Kazemnezhad E. STUDYING THE ASSOCIATION BETWEEN ATORVASTATIN AND TOTAL PLASMA HOMOCYSTEINE LEVELS IN RENAL TRANSPLANT RECIPIENTS IN NORTH OF IRAN. In TRANSPLANT INTERNATIONAL 2015 Nov 1 (Vol. 28, pp. 537-537). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY-BLACKWELL.
Monfared A, Azimi SZ, Kazemnezhad E, Khosravi M, Lebadi M, Mirzajani E, Ashtiani MN. Transplantation. 2014 Dec 15; 98(11):e89-90. doi:10.1097/TP.0000000000000494.
Monfared A, Rad MA, Feizkhah M, Kazemnezhad E, Esmaeili S, Herfeh NR, Hedayatsafa R. Nephro-Urology Monthly. 2016 March 26; 8(3):e35864. doi:10.5812/numonthly.35864.